Shots:
- Based on ARCADIA and OLYMPIA studies EU approved Nemluvio for moderate-to-severe AD and PN and is now approved for SC use in pts. aged 12 and older for AD and in adults for PN who are candidates for systemic therapy
- ARCADIA 1 & 2 studies assessed Nemluvio (Q4W) + TCS ± TCI vs PBO in atopic dermatitis patients (n=1,728) for 16 & 48wks., respectively. It showed improved co-1EPs & all key 2EPs as well as itch relief at wk.1
- OLYMPIA 1 & 2 trials assessed Nemluvio (Q4W) vs PBO in PN patients (n=560) for 16 & 24wks., respectively. It achieved its co-1EPs & all key 2EPs, depicting improved itch & skin nodules at wk.16, with fast itch reductions at wk.4
Ref: Galderma | Image: Galderma
Related News:- Galderma’s Nemluvio (Nemolizumab) Secures the US FDA’s Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
